Psychiatric symptoms improved significantly within 16 days of inpatient cannabis detoxification | Research

The takeaway

In 35 chronic cannabis users undergoing supervised detox, psychiatric symptoms improved substantially within 16 days, though patients rated their own distress higher than clinicians observed.

Read this if you're going through or considering cannabis detox and want to know what to expect.

Effect sizes 0.7-1.4 for psychiatric improvement within 16 days

What the researchers found

Thirty-five chronic cannabis-dependent individuals were monitored during inpatient detoxification using both clinician-rated and self-reported psychiatric scales. At admission, nearly 90% showed no or only mild depression, anxiety, or manic symptoms on clinician-rated scales. However, about 60% described strong psychiatric distress in self-reports.

All patients improved significantly within 16 days. Effect sizes ranged from 0.7 to 1.4 (Cohen's d), indicating medium to large improvements across all measures. THC blood levels at admission were associated with cognitive impairment and motor retardation but not with mood or anxiety symptoms.

The discrepancy between clinician observations and self-reports was attributed to withdrawal syndrome effects and executive dysfunction, which may alter patients' ability to accurately assess their own mental state.

Why it matters

This study provides a timeline for psychiatric improvement during supervised cannabis withdrawal. The 16-day improvement window and the discrepancy between how patients feel versus how they appear to clinicians are both clinically useful for managing expectations during detox.

The numbers in context

35 patients studied. 90% showed mild or no clinician-rated psychiatric symptoms at admission. 60% self-reported strong psychiatric burden. Effect sizes 0.7-1.4 (Cohen's d) for improvement over 16 days. THC levels predicted cognitive impairment and motor retardation.

How the study worked

Prospective observational study of 35 treatment-seeking chronic cannabis-dependent patients (ICD-10 criteria) without active comorbid psychiatric conditions. Assessed at admission and on abstinence days 8 and 16 using HAMD, HAMA, YMRS, BPRS, and SCL-90-R. Serum THC and metabolites measured simultaneously.

What this study cannot tell us

Small sample of 35 patients. No control group. Patients were treatment-seeking and free of active comorbid conditions, which limits generalizability. Sixteen days may not capture the full duration of withdrawal symptoms.

How to read the evidence

Small prospective observational study without a control group. Findings are descriptive of the detox experience.

When this study was published

Published in 2015 using inpatient detoxification data.

The bigger picture

Cannabis withdrawal is often perceived as mild compared to other substances, but this study shows patients experience significant subjective distress that may not be apparent to clinicians. Recognizing this gap helps improve clinical care during detoxification.

Questions still open

Do psychiatric symptoms continue improving beyond 16 days? Why do patients rate their distress so much higher than clinicians observe? Would longer monitoring reveal a different trajectory for cognitive symptoms?

Common questions

How long do cannabis withdrawal symptoms last?

In this study, significant psychiatric improvement occurred within 16 days of supervised abstinence, with medium to large effect sizes. However, 16 days may not capture the complete withdrawal timeline for all individuals.

Why might I feel worse than I look during cannabis withdrawal?

This study found patients rated their psychiatric distress much higher than clinician observations showed. The researchers attributed this gap to withdrawal effects and executive dysfunction that may alter self-perception.

Read the original research

Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum.

Drug and alcohol dependence, 155, 302-6

View on PubMed ↗Publisher’s paper ↗

Citation

Bonnet, Udo; Borda, Thorsten; Scherbaum, Norbert; Specka, Michael. (2015). Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum.. Drug and alcohol dependence, 155, 302-6. https://doi.org/10.1016/j.drugalcdep.2015.08.003